Draig Gets FDA IND OK for Ph2 Study of DT-101 in Depression
02 Oct 2025 //
GLOBENEWSWIRE
Draig Therapeutics Names Douglas E. Williams as Board Chair
15 Jul 2025 //
GLOBENEWSWIRE
Draig Launches with $140M for Neuropsychiatric Disorders
18 Jun 2025 //
GLOBENEWSWIRE

Market Place
Sourcing Support